0001193125-25-253538
SEC filingRevenue growth driven by new patient starts and PBP channel mix shift, with gross margin stable despite channel headwinds.
For the three months ended September 30, 2025, Beta Bionics reported net sales of $27.3 million, a 63% increase from $16.7 million in the same period of 2024. The growth was primarily driven by a 68% increase in new patient starts (5,334 vs. 3,180) and a higher proportion of single-use product sales, which accounted for 47% of net sales (up from 27%). Gross profit rose 70% to $15.1 million, with gross margin improving to 55.5% from 53.4%, as higher production volumes and improved manufacturing cost absorption more than offset the margin-dilutive effect of the shift toward the PBP channel. Operating expenses increased 62% to $32.2 million, led by sales and marketing (+66%) and R&D (+59%) investments to support commercialization and product development. Net loss widened to $14.2 million from $9.7 million, though adjusted EBITDA improved sequentially from -$15.5 million in Q1 2025 to -$12.2 million in Q3 2025, reflecting operating leverage.
The company operates through two reimbursement channels: DME and PBP. In Q3 2025, DME channel sales represented 77% of net sales (down from 87% in Q3 2024), while PBP channel sales grew to 23% (up from 13%). The PBP channel is a strategic priority because, despite lower upfront revenue, it generates higher lifetime margins due to higher per-unit pricing on single-use products. PBP-reimbursed new patient starts reached a low-30% share in Q3 2025, up from high-single digits in Q3 2024, driven by expanded pharmacy benefit contracts. The mix shift continues to pressure gross margins, but the impact was offset by higher volumes and manufacturing efficiencies in the current quarter.
Management expects operating expenses to increase significantly as the company invests in commercialization, R&D (including a patch pump and bihormonal system), and expansion into type 2 diabetes. The company believes existing cash, cash equivalents, and investments of $274.0 million as of September 30, 2025, along with product sales, will fund operations through the first half of 2028. Key strategic priorities include directing demand toward the PBP channel, expanding the sales force, and leveraging partnerships with Dexcom and Abbott. Seasonality is expected to cause lower sales in Q1 versus Q4 each year due to insurance deductible resets.
Beta Bionics held $38.5M in cash and cash equivalents and $235.5M in marketable securities (short-term U.S. Treasury bills of $190.2M and long-term Treasury notes of $45.3M) as of September 30, 2025. Total liquidity of $274.0M reflects the January 2025 IPO and concurrent private placement that generated net proceeds of $206.0M. The company has no debt, with total liabilities of $35.3M primarily comprising operating lease liabilities ($7.7M), deferred revenue ($4.3M), and accrued expenses. Stockholders' equity improved to $294.8M from a deficit of $(245.4)M at year-end 2024, driven by the conversion of preferred stock and warrant liabilities into common stock.
Purchase commitments total $11.9M, consisting of $2.6M remaining for the Xeris Phase 3 clinical supply arrangement and $9.3M in non-cancellable operating lease obligations. The Xeris commitment is part of a collaboration for glucagon products; the company has already paid $2.5M of the total $5.1M development/manufacturing costs. Operating leases include office and manufacturing space in California with expiration dates through 2032. Additionally, the company has ongoing royalty obligations to Xeris (low double-digit percentages of net sales) and to Boston University for licensed technology (incurred $2.2M in nine months 2025).
Beta Bionics allocates capital primarily toward R&D, sales & marketing, and manufacturing scale-up. Capital expenditures totaled $3.4M for the nine months ended September 30, 2025, representing 5.0% of net sales. The company did not repurchase shares or pay dividends. The substantial cash position from the IPO provides funding for continued commercialization and development activities.
The company operates as a single operating segment: diabetes management through the iLet system. All revenues ($68.1M for nine months 2025) are generated in the United States, with roughly 78% from the durable medical equipment (DME) channel and 22% from the pharmacy benefit plan (PBP) channel. Net sales grew 52.5% year-over-year, driven by increased iLet placements and recurring single-use product revenue.
Beta Bionics reported a net loss of $59.7M for the nine months ended September 30, 2025, compared to a net loss of $36.6M in the prior year period. Operating cash flow was negative at $42.3M, representing a cash burn that was 71% of the net loss (versus 93% in the prior period), indicating a relative improvement in cash conversion due to non-cash charges such as stock-based compensation ($12.1M) and fair value changes in warrant liabilities ($12.5M). Working capital changes consumed additional cash, notably a $7.7M increase in inventories and a $5.4M increase in prepaid expenses, partially offset by increases in accounts payable and deferred revenue.
Capex was modest at $3.4M (8% of operating cash flow), consistent with a commercial-stage medical device company that is still scaling. The company did not pay dividends or repurchase shares. The significant increase in investing cash outflow ($163.5M) was primarily driven by purchases of short-term and long-term investments, funded by the substantial financing inflow of $213.8M from stock issuances. Overall, the company remains in a growth and investment phase, relying on equity financing to support operations and investment activities. No free cash flow is disclosed; however, given negative operating cash flow and modest capex, the company is not yet generating positive free cash flow.